Litcius/Paper detail

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial

Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, William E Sanchez, Anita Scribner, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Ellen Koenig

2022The Lancet HIV102 citationsDOI

Topics & Concepts

EmtricitabineMedicineTenofovir alafenamideInternal medicineDosingRegimenViral loadHuman immunodeficiency virus (HIV)Antiretroviral therapyVirologyHIV/AIDS drug development and treatmentHIV Research and TreatmentHIV-related health complications and treatments
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial | Litcius